DENTSPLY SIRONA Inc. (XRAY) Is At $43.77 Formed Wedge; Adamas Pharmaceuticals, Inc. (ADMS) Had 6 Analysts Last Week

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Logo

DENTSPLY SIRONA Inc. (XRAY) formed wedge down with $39.83 target or 9.00% below today’s $43.77 share price. DENTSPLY SIRONA Inc. (XRAY) has $9.96B valuation. The stock increased 0.30% or $0.13 during the last trading session, reaching $43.77. About 1.38 million shares traded. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has declined 26.16% since July 1, 2017 and is downtrending. It has underperformed by 38.73% the S&P500. Some Historical XRAY News: 06/05/2018 – Dentsply Sirona Sees FY18 EPS $2.55-EPS $2.65; 15/05/2018 – Healthcor Adds Dentsply, Exits CVS, Cuts Medtronic: 13F; 26/03/2018 – Dentsply Sirona: Planning to Incur Additional Investments, Expenses; 17/05/2018 – Dentsply 11.3% Owned by Hedge Funds; 15/05/2018 – Select Equity Adds Zebra Tech, Exits Signet, Cuts Dentsply: 13F; 26/03/2018 – DENTSPLY SIRONA REPORTS PURCHASE OF TECHNOLOGY SOLUTIONS PROVID; 16/03/2018 – FBO:Veteran Aff: Veterans Affairs Contract Award – 65–DENTSPLY North America LLC – new award 01/15/2018 – 01/14/2023 – 65IIC; 26/03/2018 – DENTSPLY SIRONA REPORTS PURCHASE OF ORAMETRIX; 25/04/2018 – Dentsply Sirona Declares Quarterly Cash Dividend; 26/03/2018 – Dentsply Sirona Announces Acquisition Of Technology Solutions Provider OraMetrix

Among 6 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamas Pharmaceuticals had 11 analyst reports since January 23, 2018 according to SRatingsIntel. The rating was maintained by Mizuho on Tuesday, January 23 with “Buy”. The firm earned “Buy” rating on Wednesday, April 4 by Leerink Swann. As per Thursday, February 22, the company rating was maintained by Piper Jaffray. The firm earned “Buy” rating on Friday, June 22 by Mizuho. The company was maintained on Tuesday, February 20 by Evercore. Mizuho maintained the stock with “Buy” rating in Tuesday, February 20 report. The firm earned “Buy” rating on Thursday, April 19 by Mizuho. Needham maintained the shares of ADMS in report on Friday, February 23 with “Buy” rating. The stock has “Buy” rating by Mizuho on Friday, March 9. Piper Jaffray maintained the shares of ADMS in report on Tuesday, January 30 with “Buy” rating. See Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) latest ratings:

22/06/2018 Broker: Mizuho Rating: Buy New Target: $70.0000 Maintain
19/04/2018 Broker: Mizuho Rating: Buy New Target: $49.0000 Maintain
04/04/2018 Broker: Leerink Swann Rating: Buy New Target: $31.0000 Initiate
27/03/2018 Broker: Bank of America Rating: Buy New Target: $39 Initiates Coverage On
09/03/2018 Broker: Mizuho Rating: Buy New Target: $49.0 Maintain
22/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $49.0 Maintain
23/02/2018 Broker: Needham Rating: Buy New Target: $40.0 Maintain
20/02/2018 Broker: Evercore Rating: Buy New Target: $85.0 Maintain
20/02/2018 Broker: Mizuho Rating: Buy New Target: $48.0 Maintain
30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $55.0 Maintain

The stock increased 2.30% or $0.58 during the last trading session, reaching $25.83. About 541,945 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 88.75% since July 1, 2017 and is uptrending. It has outperformed by 76.18% the S&P500. Some Historical ADMS News: 26/03/2018 – Adamas Pharma Presenting at Conference Tomorrow; 15/03/2018 – ADAMAS PHARMACEUTICALS – THE 2 POOLED PHASE 3 STUDIES SHOWED GOCOVRI-TREATED PATIENTS EXPERIENCED 41 PCT FALL IN DYSKINESIA FROM BASELINE AT WEEK 12; 21/04/2018 – DJ Adamas Pharmaceuticals Inc, Inst Holders, 1Q 2018 (ADMS); 15/03/2018 – ADAMAS PHARMACEUTICALS – ANNOUNCES RESULTS FROM TWO POOLED PHASE 3 STUDIES IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA; 29/03/2018 – ADAMAS FIN ASIA LTD – UPDATE ON DISPOSAL OF INTEREST IN GLOBAL PHARM; 10/04/2018 – Adamas Pharma at Deutsche Bank Health Care Conference May 8; 06/03/2018 ADAMAS INCORPORATION PCL – APPOINTS KRIANGKRAI SIRAVANICHKAN AS ACTING CEO IN PLACE OF PATTANAN APIRAYOTHIN; 27/04/2018 – Adamas Finance Asia: Fortune Insight Unable to Complete Global Pharm Buy; 19/04/2018 – ADAMAS PHARMACEUTICALS INC – SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY-PUBLISHED CONTROLLED PHASE 3 STUDIES; 03/05/2018 – Adamas Pharma Presenting at Bank of America Conference May 16

More important recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Globenewswire.com which released: “Adamas Announces New Employment Inducement Grant” on June 08, 2018, also Nasdaq.com published article titled: “Adamas Presents New Data Analysis Demonstrating that GOCOVRIâ„¢ Reduces Transitions between Dyskinesia and …”, Seekingalpha.com published: “What Does The Rate Hike Mean For Stocks? – Cramer’s Mad Money (6/13/18)” on June 14, 2018. More interesting news about Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was released by: Seekingalpha.com and their article: “Aptinyx IPO: It Collaborated With Allergan, But Shares Are Not Cheap” with publication date: June 27, 2018.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $696.95 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.

Among 10 analysts covering DENTSPLY SIRONA Inc (NASDAQ:XRAY), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. DENTSPLY SIRONA Inc has $73.0 highest and $5200 lowest target. $60.50’s average target is 38.22% above currents $43.77 stock price. DENTSPLY SIRONA Inc had 16 analyst reports since January 4, 2018 according to SRatingsIntel. H.C. Wainwright maintained DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on Thursday, January 18 with “Hold” rating. H.C. Wainwright maintained DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on Monday, March 5 with “Neutral” rating. The firm earned “Buy” rating on Tuesday, May 8 by Stifel Nicolaus. The firm earned “Hold” rating on Tuesday, March 27 by H.C. Wainwright. Credit Suisse maintained it with “Outperform” rating and $69 target in Friday, March 2 report. Morgan Stanley maintained DENTSPLY SIRONA Inc. (NASDAQ:XRAY) rating on Thursday, June 14. Morgan Stanley has “Overweight” rating and $54 target. JP Morgan maintained the shares of XRAY in report on Monday, March 5 with “Overweight” rating. The rating was downgraded by Northcoast on Tuesday, June 5 to “Neutral”. The firm earned “Buy” rating on Monday, April 16 by Jefferies. H.C. Wainwright maintained the stock with “Hold” rating in Tuesday, May 8 report.

Since January 8, 2018, it had 2 insider buys, and 4 selling transactions for $2.45 million activity. 22,500 shares were bought by Casey Donald M Jr., worth $1.00M on Wednesday, May 9. On Monday, January 8 the insider BRANDT ERIC sold $436,068. Another trade for 414 shares valued at $19,316 was made by COLEMAN MICHAEL J on Thursday, May 10. $2.24 million worth of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) was bought by ALEXOS NICHOLAS W. $64,341 worth of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) was sold by ALFANO MICHAEL C on Wednesday, May 30.

Analysts await DENTSPLY SIRONA Inc. (NASDAQ:XRAY) to report earnings on August, 8. They expect $0.60 earnings per share, down 7.69% or $0.05 from last year’s $0.65 per share. XRAY’s profit will be $136.46 million for 18.24 P/E if the $0.60 EPS becomes a reality. After $0.45 actual earnings per share reported by DENTSPLY SIRONA Inc. for the previous quarter, Wall Street now forecasts 33.33% EPS growth.

Investors sentiment increased to 0.5 in 2018 Q1. Its up 0.30, from 0.2 in 2017Q4. It increased, as 1 investors sold DENTSPLY SIRONA Inc. shares while 3 reduced holdings. 0 funds opened positions while 2 raised stakes. 569,543 shares or 38.02% more from 412,640 shares in 2017Q4 were reported. West Oak Cap Ltd Liability owns 0% invested in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) for 6,290 shares. Cardinal Mngmt reported 1.1% stake. Tirschwell Loewy invested in 1.74% or 250,918 shares. Cibc Ww Markets Corporation holds 242,573 shares or 0.13% of its portfolio. Gemmer Asset Limited Co holds 0% or 241 shares.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart